Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2014

Conditions
Muscle WastingNon Small Cell Lung Cancer
Interventions
DRUG

GTx-024

subjects will be randomized to receive GTx-024 for the full duration of the trial.

DRUG

placebo

subject will receive placebo for the duration of the trial

Trial Locations (27)

14642

GTx Investigative Site, Rochester

17604

GTx Investigative Site, Lancaster

27103

GTx Investigative Site, Winston-Salem

27215

GTx Investigative Site, Burlington

28401

GTx Investigative Site, Wilmington

28731

GTx Investigative Site, Flat Rock

29303

GTx Investigative Site, Spartanburg

32763

GTx Investigative Site, Orange City

33133

GTx Investigative Site, Miami

33180

GTx Investigative Site, Aventura

33612

GTx Investigative Site, Tampa

35211

GTx Investigative Site, Birmingham

38801

GTx Investigative Site, Tupelo

41101

GTx Investigative Site, Ashland

44406

GTx Investigative Site, Canfield

44718

Gabrail Cancer Center, Canton

44870

GTx Investigative Site, Sandusky

46260

GTx Investigative Site, Indianapolis

48081

GTx Investigative Site, Saint Clair Shores

59405

GTx Investigative Site, Great Falls

60076

GTx Investigative Site, Skokie

61615

GTx Investigative Site, Peoria

62526

GTx Investigative Site, Decatur

78665

GTx Investigative Site, Round Rock

90813

GTx Investigative Site, Long Beach

97213

GTx Investigative Site, Portland

01742

GTx Investigative Site, Concord

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GTx

INDUSTRY

NCT01355484 - Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter